The short version
6 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Xeljanz
tofacitinib · TOFACITINIB CITRATE 1 mg/mL · Solution · Oral · U.S. Pharmaceuticals
NDC 63539-0029-02 · 1 BOTTLE in 1 CARTON / 240 mL in 1 BOTTLE · NDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00069-1029-02) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$21.79per unit
middle half $21.02–$22.28 · 3,381 plans · Apr 1, 2026
Est. net of rebatesⓘ
$13.08–$16.34
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
62%of plans cover it
tier 5 · prior auth 97% · step therapy 0% · qty limit 91%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $5,630.23 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA213082
- TE code
- AA
- Approval date
- Sep 25, 2020
- Patents / exclusivity
- 2 patents, 2 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | PED | Aug 21, 2028 |
| exclusivity | M-14 | Feb 21, 2028 |
| patent | RE41783*PED | Jun 8, 2026 |
| patent | RE41783 | Dec 8, 2025 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of tofacitinib (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Hikma Pharmaceuticals USA Inc. | TOFACITINIB CITRATE 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| IPG Pharmaceuticals, Inc | TOFACITINIB CITRATE 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Novadoz Pharmaceuticals LLC | TOFACITINIB CITRATE 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Pfizer Laboratories Div Pfizer Inc | TOFACITINIB CITRATE 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industries, Inc. | TOFACITINIB CITRATE 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| U.S. Pharmaceuticals | TOFACITINIB CITRATE 1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Xeljanz — NDC 63539-0029-02," retrieved September 3, 2026, https://drugdashboards.com/drug/63539002902.
Free to cite with attribution — see how the data is put together.